Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29369517 | 0.91 | MAOB (0.78) | MAOBSMN1; SMN2MAPTCYP2C19L3MBTL1 | |
| SCHEMBL384341 | 0.91 | MAOB (0.78) | MAOBSMN1; SMN2MAPTCYP2C19L3MBTL1 | |
| SCHEMBL10797158 | 0.90 | MAOB (0.72) | MAOBSMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL8888358 | 0.90 | LRRK2 (0.63) | MAOBSMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL6404086 | 0.90 | HDAC8 (0.60) | MAOBSMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL31550547 | 0.90 | HDAC8 (0.60) | MAOBSMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL1962771 | 0.87 | MAOB (0.64) | MAOBSMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL11557673 | 0.87 | KDM4E (0.60) | MAOBSMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL5228333 | 0.87 | HDAC8 (0.57) | MAOBSMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL29466867 | 0.87 | MAOB (0.68) | MAOBSMN1; SMN2KDM4EMAPTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230139366-A1 | BRARTEMICIN ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2023-05-04 | — | — | US | disclosed |
| EP-3355699-B1 | BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2 | ONCOTHERAPY SCIENCE INC (JP) | 2021-03-31 | — | — | EP | disclosed |
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139366-A1 | BRARTEMICIN ANALOGUES | RXFP1, RXFP2, RXFP4 | MAOB 4572/4885SMN1; SMN2 3927/4885RAB9A 1030/4885 |
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | MAOB 1228/4885SMN1; SMN2 4633/4885RAB9A 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.